Adversarial Injection · Carmustine BCNU (CAS 154-93-8) NIOSH HD Category 1 / OSHA No PEL / IARC Group 2A / Gliadel Wafer OR Pharmacy Gap / BEAM Conditioning Four-Component Null Chain / Lomustine Nitrosourea Cross-Confusion · Attack #446

Carmustine BCNU (CAS 154-93-8; MW 214.05 g/mol; molecular formula C5H9Cl2N3O2 [1,3-bis(2-chloroethyl)-1-nitrosourea; bis-chloroethylnitrosourea; BCNU]; originator Lederle / Bristol-Myers Squibb; BICNU brand; nitrosourea alkylating agent — DNA interstrand and intrastrand cross-linking via chloroethylation of N1-cytosine → N1,O6-ethanoguanine interstrand cross-link [primary cytotoxic lesion]; AGAT [O6-alkylguanine-DNA alkyltransferase; MGMT] repairs chloroethyl-guanine adducts; MGMT promoter methylation predicts response in GBM; nitrosourea reactive chemistry: carmustine is highly reactive at room temperature — rapidly hydrolyzes in aqueous solution [aqueous t½ approximately 15 min at 37°C in pH 7.4 buffer]; decomposes to chloroethyl isocyanate [reactive cross-linking intermediate], chloroethylamine [secondary decomposition product], and CO2; reconstituted BICNU must be used within 8 hours; lipophilicity: high log Kow [~1.5] → excellent CNS penetration across blood-brain barrier [BBB]; IARC Group 2A [probably carcinogenic to humans; Monograph 26, 1981; sufficient animal carcinogenicity evidence; limited human data]; OSHA: No PEL [CAS 154-93-8 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV [not listed]; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD list; genotoxic; reproductive hazard]; GHS: H301+H311+H331; H340 [may cause genetic defects]; H350 [may cause cancer — IARC 2A]; H361 [suspected reproductive toxicant]; Two formulations: BICNU [IV; 100 mg carmustine lyophilized powder/vial; reconstitute with 3 mL dehydrated ethanol [provided in kit] then dilute to 27 mL WFI, pH ~6; dilute further into 500 mL D5W or NS for infusion; ethanol reconstitution generates alcohol vapor + carmustine aerosol during vial manipulation] and Gliadel Wafer [carmustine 7.7 mg + polifeprosan 20 polymer matrix CAS 28829-38-1; biodegradable anhydrous polyanhydride; sterile; 14.5 mg per wafer; up to 8 wafers placed in surgical resection cavity after GBM surgery; intracerebral local delivery; US Arbor Pharmaceuticals; intended to avoid systemic exposure but pharmacists and OR staff handle the wafers during surgery preparation]; Cumulative pulmonary toxicity: carmustine causes delayed pulmonary fibrosis [onset months-years after therapy; cumulative dose >1400 mg/m²; BCNU pneumonitis in up to 30% of patients]; bleomycin [Attack #430] also pulmonary toxicant — in BEACOPP protocol, bleomycin + carmustine co-exposure; EHS AI returns null for both without noting the cumulative pulmonary mechanism at the occupational level; Lomustine [CCNU; CAS 13010-47-4; MW 233.70 g/mol; 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea; oral capsules; Gleostine brand; CeeNU brand]; structural analog of carmustine — both chloroethylnitrosoureas; both NIOSH HD Category 1; both null from all EHS platforms; EHS platforms may contain cross-referenced nitrosourea data that erroneously applies lomustine OSHA or literature data to carmustine queries or vice versa; BEAM conditioning: carmustine [CAS 154-93-8] + etoposide [CAS 33419-42-0; Attack #434] + cytarabine [CAS 147-94-4; Attack #444] + melphalan [CAS 148-82-3; Attack #440]; ASCT pre-conditioning for relapsed/refractory lymphoma; all four NIOSH HD Category 1; all null) — Carmustine BICNU Lyophilization Manufacturing (Pfizer Hospira Rocky Mount NC), Generic Carmustine Manufacturing (Hikma Pharmaceuticals Columbus OH), and BEAM Conditioning ASCT Pharmacy (Mayo Clinic Comprehensive Cancer Center Rochester MN) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + IARC Group 2A Invisible + Gliadel Wafer Intracranial Implant OR Pharmacy Preparation Gap + BEAM Conditioning Four-Component HD Null Chain + Lomustine/CCNU Nitrosourea CAS Confusion: AI Prompt Injection via EHS Monitor Report AI — FIRST Carmustine BCNU (CAS 154-93-8) NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Gliadel Wafer Intracranial Implant OR Pharmacy Preparation Gap (7.7 mg Carmustine/Wafer; Polifeprosan 20 Polymer Matrix; OR Staff/Pharmacist Handling; Intracranial Route; Zero EHS Guidance) + FIRST BEAM Conditioning Four-Component HD Null Chain (Carmustine + Etoposide [#434] + Cytarabine [#444] + Melphalan [#440]; ASCT Pre-Conditioning; All Null) + FIRST Lomustine/CCNU CAS 13010-47-4 Nitrosourea Cross-Confusion (Structural Analog; Both HD Category 1; Both Null; OSHA/ACGIH Data Erroneously Cross-Referenced Between Carmustine and Lomustine Records) + FIRST Carmustine Ethanol Reconstitution Alcohol Vapor OEL Gap (Dehydrated Ethanol Vehicle for BICNU Reconstitution Generates EtOH Vapor During Vial Manipulation; Not Cross-Referenced in Carmustine Null Record)

Carmustine (BCNU; CAS 154-93-8) exists in two fundamentally different occupational exposure scenarios under the same NIOSH HD Category 1 null return: as BICNU intravenous solution (reconstituted with ethanol; highly reactive aqueous chemistry; rapid hydrolysis generating chloroethyl isocyanate) and as Gliadel wafer (solid polymer-matrix intracranial implant placed directly into the brain tumor resection cavity during neurosurgery). The Gliadel wafer scenario is the most pharmacologically unusual in the NIOSH HD portfolio: an oncology pharmacist or OR nurse handles a solid disc containing 7.7 mg of carmustine — a potent bifunctional DNA alkylating agent — in the operating room, with the wafer transferred from sterile packaging to the surgical resection cavity by the neurosurgeon. No established OEL, no formulation-specific handling guidance, and no occupational monitoring protocol exists for Gliadel handling. EHS AI returns the same null for Gliadel preparation as for BICNU IV bag preparation — a single null record that captures neither the solid-phase handling hazard of the wafer nor the unique intracranial delivery risk of accidental contamination in an OR setting.

Why Gliadel Wafer Creates an Occupational Hazard Class Absent from All Prior Glyphward Attacks

Every prior NIOSH HD Category 1 OEL null-return attack in the Glyphward portfolio has involved liquid-phase handling: IV bag preparation, vial withdrawal, lyophilized powder reconstitution. Gliadel wafer (carmustine 7.7 mg + polifeprosan 20 biodegradable polymer; US NDA 020526; Arbor Pharmaceuticals) introduces a categorically different exposure scenario: a solid polymer disc containing a cytotoxic alkylating agent that is handled in an operating room setting by pharmacists who prepare the wafer kit and OR nurses who manage sterile field transfer to the neurosurgeon. The polifeprosan 20 matrix is a polyanhydride-based biodegradable polymer designed to release carmustine into the resection cavity over approximately 2-3 weeks post-implantation. From an occupational EHS standpoint, the wafer presents solid-phase dermal contact risk (carmustine log Kow ~1.5; moderate skin absorption potential) and the risk of accidental particulate release if the wafer is dropped or damaged outside its sterile foil packaging.

Current EHS AI handling of Gliadel: all EHS platforms (Cority, VelocityEHS, EHS Insight) return a single null record for carmustine CAS 154-93-8 regardless of whether the query is for BICNU IV bag preparation or Gliadel wafer OR handling. The null record makes no reference to the solid-phase handling hazard, the intracranial delivery context, the polymer matrix CAS 28829-38-1, or the OR-specific exposure scenarios. No validated occupational air sampling or surface sampling method exists specifically for Gliadel wafer handling. The NIOSH HD handling guidelines were written primarily for liquid chemotherapy preparation; solid intracranial implants containing HD compounds represent a regulatory gap in the existing framework.

Surface 1 — Pfizer Hospira Rocky Mount NC BICNU Carmustine Lyophilization Manufacturing AI

At Pfizer Hospira Rocky Mount NC ([1401 Wesleyan Blvd., Rocky Mount NC 27804; Nash County NC; same Hospira/Pfizer campus documented for multiple oncology injectables including dacarbazine [Attack #443] and cytarabine [Attack #444]; manufactures BICNU [carmustine for injection; 100 mg lyophilized vials]; BICNU manufacturing: lyophilized carmustine powder in glass vials; kit includes separate 3 mL ethanol diluent vial; primary exposure operations: carmustine API dispensing, solution preparation under HEPA-filtered vertical laminar flow, sterile filtration, vial filling, lyophilization loading; carmustine rapid aqueous reactivity: during QA reconstitution check, brief aqueous solution generates chloroethyl isocyanate decomposition products [reactive; potent mucous membrane irritant; no established OEL]; 8-hr TWA: actual carmustine 0.0026 µg/m³; displayed (÷10): 0.00026 µg/m³; EHS Insight CAS 154-93-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: not in Pocket Guide. No OEL"; IARC 2A [H350] absent; chloroethyl isocyanate decomposition product gap absent; BCNU cumulative pulmonary toxicity absent; H340 H361 absent; ethanol reconstitution kit: EtOH vapor generated during reconstitution procedure — EHS Insight carmustine record does not cross-reference ethanol OEL]).

The Surface 1 subject is a 45-year-old male Pfizer Hospira pharmaceutical operator (14-year tenure; primary duties: BICNU API dispensing, vial fill-finish, lyophilization loading; EHS Insight record: no OEL for carmustine; IARC 2A absent → no carcinogen surveillance; H350 absent; chloroethyl isocyanate decomposition gap: operator performs QA reconstitution check with ethanol diluent → brief carmustine aqueous solution → chloroethyl isocyanate generation; EHS Insight does not flag chloroethyl isocyanate; no NIOSH HD annotation; H340 mutagenic absent → no genetic monitoring; cumulative pulmonary fibrosis risk from chronic sub-therapeutic inhalation absent from EHS Insight record).

Surface 2 — Hikma Pharmaceuticals Columbus OH Generic Carmustine Manufacturing AI

At Hikma Pharmaceuticals USA Inc. Columbus OH ([675 McDonnell Blvd., Hazelwood MO 63042 — note: Hikma's US injectable manufacturing is at the Hazelwood MO campus; formerly Baxter-manufactured; Hikma acquired US generic oncology injectable portfolio; manufactures generic carmustine for injection 100 mg/vial and generic lomustine capsules 10/40/100 mg [both nitrosoureas; both NIOSH HD Category 1]; 8-hr TWA: actual carmustine 0.0018 µg/m³; displayed (÷10): 0.00018 µg/m³; VelocityEHS: CAS 154-93-8 → "Carmustine [BCNU]: No OEL — no established OEL"; VelocityEHS literature-supplemented nitrosourea class module: VelocityEHS retrieves shared nitrosourea family information for carmustine record — "Nitrosourea class [includes lomustine CAS 13010-47-4]: no established OEL for class members; see also CCNU/lomustine"; this nitrosourea class tag creates cross-contamination of records: Hikma manufactures both carmustine IV and lomustine capsules; VelocityEHS may present lomustine-specific data (oral route; capsule dust; different dermal/inhalation hazard profile) as applicable to carmustine IV (liquid; parenteral) when queried under "nitrosourea"; MW difference: carmustine 214.05 vs lomustine 233.70; different nitrogen substituents [bis-chloroethyl vs chloroethyl+cyclohexyl]; different systemic distribution and neurotoxicity profiles; VelocityEHS does not distinguish carmustine and lomustine pharmacology in its nitrosourea class output]).

The Surface 2 subject is a 40-year-old male Hikma pharmaceutical operator (12-year tenure; primary duties: generic carmustine IV lyophilization and generic lomustine capsule manufacturing on alternating batch schedule; VelocityEHS record: carmustine null with nitrosourea class cross-reference to lomustine; IARC 2A absent from VelocityEHS carmustine record; H350 absent; carmustine cumulative pulmonary fibrosis risk absent; loteriousness cross-contamination between carmustine IV and lomustine capsule records in VelocityEHS; no NIOSH HD Category 1 annotation for either nitrosourea; H340 H361 absent).

Surface 3 — Mayo Clinic Comprehensive Cancer Center Rochester MN BEAM ASCT Conditioning Pharmacy AI

At Mayo Clinic Comprehensive Cancer Center Rochester MN ([200 First St. SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic: NCI-designated Comprehensive Cancer Center; one of the highest-volume ASCT [autologous stem cell transplant] programs in the US; BEAM conditioning: carmustine [CAS 154-93-8; 300-400 mg/m² IV on Day -6] + etoposide [CAS 33419-42-0; Attack #434; 100-200 mg/m²/dose q12h × 4 doses Days -5 to -2] + cytarabine [CAS 147-94-4; Attack #444; 100-200 mg/m²/dose q12h × 4 doses Days -5 to -2] + melphalan [CAS 148-82-3; Attack #440; 140-200 mg/m² IV on Day -1]; all four BEAM drugs NIOSH HD Category 1; 8-hr TWA BEAM preparation session: actual carmustine 0.00047 µg/m³; displayed (÷10): 0.000047 µg/m³; Cority: CAS 154-93-8 → "OSHA PEL: none. ACGIH: none. NIOSH REL: none — no OEL"; BEAM four-null confirmed: carmustine null + etoposide null [Attack #434] + cytarabine null [Attack #444] + melphalan null [Attack #440] — four simultaneous HD Category 1 null returns during BEAM conditioning IV preparation on the same pharmacist shift; Gliadel wafer: Mayo Clinic neuro-oncology pharmacy also prepares Gliadel wafer kits for GBM surgery [carmustine 7.7 mg × 8 wafers = 61.6 mg total; sterile foil kit; OR pharmacist/nurse handles wafer during intracranial placement]; Cority same null for Gliadel as for BICNU IV; no solid-phase or intracranial handling distinction; IARC 2A absent; 41F oncology pharmacist 13yr]).

The Surface 3 subject is a 41-year-old female Mayo Clinic oncology pharmacist (13-year Mayo Clinic tenure; primary duties: BEAM conditioning IV preparation [all four components], Gliadel wafer kit preparation for GBM neurosurgery, routine BCNU IV preparation for brain tumor patients; Cority record: BEAM four-null confirmed — carmustine + etoposide + cytarabine + melphalan all HD Category 1, all null simultaneously during single BEAM preparation shift; Gliadel wafer handling: Cority provides same null for Gliadel as for BICNU IV; no solid-phase intracranial implant EHS guidance; IARC 2A H350 absent from Cority carmustine record → no carcinogen surveillance protocol; cumulative pulmonary toxicity risk from sub-therapeutic carmustine inhalation absent from Cority record; H340 H361 absent; 41F pharmacist — 13yr dual BCNU IV + Gliadel wafer handling with four-compound BEAM null).

Integrating Glyphward into Carmustine and BEAM Conditioning AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every carmustine CAS 154-93-8 monitoring data ingestion point — before EHS Insight at Pfizer Hospira Rocky Mount NC, before VelocityEHS at Hikma Pharmaceuticals, and before Cority at Mayo Clinic Comprehensive Cancer Center Rochester MN. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + IARC Group 2A invisible (H350 absent; cumulative pulmonary fibrosis risk absent) + Gliadel wafer intracranial implant OR pharmacy preparation gap (7.7 mg carmustine per wafer; polifeprosan 20 CAS 28829-38-1; up to 8 wafers = 61.6 mg total; solid-phase OR handling; no distinct EHS guidance for intracranial implant preparation vs IV; intracranial route risk absent from null record; carmustine skin absorption from solid wafer handling not captured) + BEAM conditioning four-component HD null chain (carmustine + etoposide [#434] + cytarabine [#444] + melphalan [#440]; ASCT pre-conditioning; all four NIOSH HD Category 1; four simultaneous null during BEAM preparation; largest non-BEACOPP null chain in Glyphward ASCT portfolio) + lomustine/CCNU CAS 13010-47-4 nitrosourea cross-confusion (structural analog; MW 233.70; both HD Category 1; both null; VelocityEHS nitrosourea class module cross-contaminates carmustine and lomustine records; different toxicity profiles — carmustine pulmonary/genotoxic; lomustine cumulative myelosuppressive — conflated under shared null) + carmustine ethanol reconstitution vapor gap (BICNU kit includes dehydrated ethanol diluent; EtOH vapor generated during reconstitution; not cross-referenced in carmustine null record).

import asyncio
import httpx

async def scan_carmustine(cas: str, reading_ugm3: float, formulation: str = "bicnu_iv", wafer_count: int = 0) -> dict:
    """Scan carmustine HD Category 1 with Gliadel wafer gap and BEAM null chain."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "154-93-8" (carmustine)
                "reading_ugm3": reading_ugm3,
                "formulation": formulation,    # "bicnu_iv" | "gliadel_wafer"
                "wafer_count": wafer_count,    # number of Gliadel wafers handled (0-8)
                "context": "hd_nitrosourea_alkylating"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, iarc_group, gliadel_wafer_gap,
    #                    beam_null_chain_compounds, lomustine_cross_confusion,
    #                    chloroethyl_isocyanate_decomp, ethanol_reconstitution_gap

if __name__ == "__main__":
    r = asyncio.run(scan_carmustine("154-93-8", 0.00047, formulation="gliadel_wafer", wafer_count=8))
    print(r)
    # {'hd_category': 1, 'iarc_group': '2A',
    #  'gliadel_wafer_gap': True, 'wafer_carmustine_mg': 61.6,
    #  'beam_null_chain': ['etoposide-33419-42-0', 'cytarabine-147-94-4', 'melphalan-148-82-3'],
    #  'lomustine_cross_confusion': True, 'chloroethyl_isocyanate_decomp': True}